A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer

Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH and Cordon-Cardo C.

Division of Molecular Pathology, Computational Biology Center, and Departments of Medicine and Urology, Memorial Sloan-Kettering Cancer Center, New York, New York; Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; and BIOPAT, Grup Assistencia, Barcelona, Spain


Purpose: The HDM2 gene represents one of the central nodes in the p53 pathway. A recent study reported the association of a single nucleotide polymorphism (SNP309) in the HDM2 promoter region with accelerated […]


Comparison of fluorescence in situ hybridization -FISH- and conventional cytology for early detection of urothelial carcinoma

Nadina Erill 1, Anna Colomer 1, Míriam Gorriz 1,2, Naim Hannaoui 3, Ruth Román 1, Maria Conangla 2, Josep M Banús 3, Carlos Cordon-Cardo 4, Xavier Puig 1,2.

1BIOPAT, Grup Assistència, Barcelona, Spain; 2HISTOPAT Laboratoris, Barcelona, Spain; 3Institut Català d’Urologia i Nefrologia, ICUN; Barcelona, Spain; and 4Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.

Bladder tumors have a high recurrence rate, so treated patients are followed for detection of potential new lesions. Cystoscopy and cytology have been the standard […]


Hibridació in situ Fluorescent -FISH- en la detecció del carcinoma urotelial

N.Erill 1, A.Colomer 1, C Pubill 2, N. Hannaoui 3, R. Román 1, M.Conangla 2, JM. Banús 3, C. Cordón 1, X. Puig 1,2.

1BIOPAT, Grup Assistència; 2HISTOPAT Laboratoris, 3Institut Català d’Urologia i Nefrologia, ICUN; Barcelona.

El carcinoma urotelial de bufeta és un dels tumors malignes més freqüents al nostre entorn. S’associa a una elevada taxa de recurrència, al voltant d’un 80% dels casos, i fins a un 30% pot evolucionar cap a carcinoma invasiu. Actualment, tant el diagnòstic com el seguiment […]


Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression

Erill N 1, Colomer A 1, Verdú M 2, Román R 1, Condom E 2, Hannaoui N 3, Banús JM 3, Cordón-Cardó C 4, and Puig X 1,2.

1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; 3ICUN, Barcelona; and 4Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Altered p53 status is a frequent event in bladder cancer and reported to have prognostic significance. We studied the TP53gene and its product in 76 patients affected with urinary bladder carcinomas by immunohistochemistry (mAb DO-7), […]


La mutación del P53 en los tumores vesicales. Su valoración mediante IHQ y PCR.

N. Hannaoui, N. Erill*, A. Colomer*, E. Vicente, A. Peña, E. Gómez, M. Verdú*, R. Román*, X. Puig*, JM. Banús

Institut Català d’Urologia i Nefrologia. * BIOPAT. Biopatologia molecular, S.L. Grup Assistència.


Texto completo


Póster presentado en:


Las Palmas de Gran Canaria, España, 24-28 Mayo 2003

Abstract: Actas Urológicas Españolas 2003;27(4SUPPL 1):182.